Myriad Genetics: Myriad Genetics Selects Lundbeck as European Partner for Flurizan

SALT LAKE CITY, UT (MARKET WIRE) Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) today announced the selection of H. Lundbeck A/S for European commercialization of Flurizan(R), Myriad's lead therapeutic candidate for the treatment of Alzheimer's disease. [read full story]                    

Add Comment
There are also 24 related articles
View all news articles about*:
*Newstin tag cloud displays all featured persons, associated organisations, related topics, regions and companies